|Bid||2.4100 x 800|
|Ask||2.4200 x 1000|
|Day's Range||2.3900 - 2.4500|
|52 Week Range||2.2800 - 5.3900|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Acer Therapeutics Inc. ( NASDAQ:ACER ) is possibly approaching a major achievement in its business, so we would like to...
The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.
Shares of Acer Therapeutics Inc. (ACER) closed 16.5% higher on Wednesday and then declined 5.51%, at the time of writing, in early trade on Thursday. The stock price moved after the pharmaceutical company and its collaboration partner, Relief Therapeutics Holding SA, received the U.S. Food and Drug Administration’s (FDA) green light to file the New Drug Application (NDA) for ACER-001. ACER-001 (sodium phenylbutyrate) is designed for the treatment of patients with various inborn errors of metabol